Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

PHASE2TerminatedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

February 29, 2004

Conditions
Pain
Interventions
DRUG

PD-217,014

Trial Locations (32)

Unknown

Pfizer Investigational Site, Warrawong

Pfizer Investigational Site, Westmead

Pfizer Investigational Site, Kippa-Ring

Pfizer Investigational Site, Maroochydore

Pfizer Investigational Site, Bedford Park

Pfizer Investigational Site, Perth

Pfizer Investigational Site, Woodville

Pfizer Investigational Site, Kelowna

Pfizer Investigational Site, Halifax

Pfizer Investigational Site, Toronto

Pfizer Investigational Site, Sherbrooke

Pfizer Investigational Site, Ste-foy

Pfizer Investigational Site, Brno

Pfizer Investigational Site, CZ-Praha 8

Pfizer Investigational Site, České Budějovice

Pfizer Investigational Site, Pilsen

Pfizer Investigational Site, Prague

Pfizer Investigational Site, Arnhem

Pfizer Investigational Site, Breda

Pfizer Investigational Site, Kampen

Pfizer Investigational Site, Roosendaal

Pfizer Investigational Site, Rotterdam

Pfizer Investigational Site, Stadskanaal

Pfizer Investigational Site, Granada

Pfizer Investigational Site, Madrid

Pfizer Investigational Site, Málaga

Pfizer Investigational Site, Seville

Pfizer Investigational Site, Barcelona

Pfizer Investigational Site, Portsmouth

Pfizer Investigational Site, Northampton

Pfizer Investigational Site, London

Pfizer Investigational Site

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00159640 - Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter